|
1
|
Gill J, Ahluwalia MK, Geller D and Gorlick
R: New targets and approaches in osteosarcoma. Pharmacol Ther.
137:89–99. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tan ML, Choong PF and Dass CR:
Osteosarcoma: Conventional treatment vs gene therapy. Cancer Biol
Ther. 8:106–117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bakhshi S and Radhakrishnan V: Prognostic
markers in osteosarcoma. Expert Rev Anticancer Ther. 10:271–287.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guise TA, O'Keefe R, Randall RL and Terek
RM: Molecular biology and therapeutics in musculoskeletal oncology.
J Bone Joint Surg Am. 91:724–732. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ramoz N, Cai G, Reichert JG, Silverman JM
and Buxbaum JD: An analysis of candidate autism loci on chromosome
2q24-q33: evidence for association to the STK39 gene. Am J Med
Genet B Neuropsychiatr Genet. 147B:1152–1158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Johnston AM, Naselli G, Gonez LJ, Martin
RM, Harrison LC and DeAizpurua HJ: SPAK, a STE20/SPS1-related
kinase that activates the p38 pathway. Oncogene. 19:4290–4297.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen LY, Zhao WH, Tian W, Guo J, Jiang F,
Jin LJ, Sun YX, Chen KM, An LL, Li GD, et al: STK39 is an
independent risk factor for male hypertension in Han Chinese. Int J
Cardiol. 154:122–127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Y, O'Connell JR, McArdle PF, Wade JB,
Dorff SE, Shah SJ, Shi X, Pan L, Rampersaud E, Shen H, et al: From
the Cover: Whole-genome association study identifies STK39 as a
hypertension susceptibility gene. Proc Natl Acad Sci USA.
106:226–231. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ramoz N, Cai G, Reichert JG, Silverman JM
and Buxbaum JD: An analysis of candidate autism loci on chromosome
2q24-q33: Evidence for association to the STK39 gene. Am J Med
Genet B Neuropsychiatr Genet. 147B:1152–1158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li NN, Tan EK, Chang XL, Mao XY, Zhang JH,
Zhao DM, Liao Q, Yu WJ and Peng R: Genetic association study
between STK39 and CCDC62/HIP1R and Parkinson's disease. PLoS One.
8:e792112013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hendriksen PJ, Dits NF, Kokame K,
Veldhoven A, van Weerden WM, Bangma CH, Trapman J and Jenster G:
Evolution of the androgen receptor pathway during progression of
prostate cancer. Cancer Res. 66:5012–5020. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Balatoni CE, Dawson DW, Suh J, Sherman MH,
Sanders G, Hong JS, Frank MJ, Malone CS, Said JW and Teitell MA:
Epigenetic silencing of Stk39 in B-cell lymphoma inhibits apoptosis
from genotoxic stress. Am J Pathol. 175:1653–1661. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li Z, Zhu W, Xiong L, Yu X, Chen X and Lin
Q: Role of high expression levels of STK39 in the growth, migration
and invasion of non-small cell type lung cancer cells. Oncotarget.
7:61366–61377. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kubben FJ, Peeters-Haesevoets A, Engels
LG, Baeten CG, Schutte B, Arends JW, Stockbrügger RW and Blijham
GH: Proliferating cell nuclear antigen (PCNA): A new marker to
study human colonic cell proliferation. Gut. 35:530–535. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gartel AL and Radhakrishnan SK: Lost in
transcription: p21 repression, mechanisms and consequences. Cancer
Res. 65:3980–3985. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang G, Yuan J and Li K: EMT transcription
factors: Implication in osteosarcoma. Med Oncol. 30:6972013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Matsuyama S, Iwadate M, Kondo M, Saitoh M,
Hanyu A, Shimizu K, Aburatani H, Mishima HK, Imamura T, Miyazono K,
et al: SB-431542 and Gleevec inhibit transforming growth
factor-beta-induced proliferation of human osteosarcoma cells.
Cancer Res. 63:7791–7798. 2003.PubMed/NCBI
|
|
18
|
Li F, Li S and Cheng T: TGF-β1 promotes
osteosarcoma cell migration and invasion through the
miR-143-versican pathway. Cell Physiol Biochem. 34:2169–2179. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Waga S, Hannon GJ, Beach D and Stillman B:
The p21 inhibitor of cyclin-dependent kinases controls DNA
replication by interaction with PCNA. Nature. 369:574–578. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang W, Luo H and Wang A: Expression of
survivin and correlation with PCNA in osteosarcoma. J Surg Oncol.
93:578–584. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cottam D and Rees R: Regulation of matrix
metalloproteinases - their role in tumor invasion and metastasis
(Review). Int J Oncol. 2:861–872. 1993.PubMed/NCBI
|
|
22
|
Yin K, Liao Q, He H and Zhong D:
Prognostic value of Twist and E-cadherin in patients with
osteosarcoma. Med Oncol. 29:3449–3455. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Massagué J: TGF-β signaling in development
and disease. FEBS Lett. 586:1833. 2012. View Article : Google Scholar : PubMed/NCBI
|
